Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Semin Arthritis Rheum ; 61: 152232, 2023 08.
Article in English | MEDLINE | ID: mdl-37348350

ABSTRACT

INTRODUCTION: Obstetric complications are more common in women with systemic lupus erythematosus (SLE) than in the general population. OBJECTIVE: To assess pregnancy outcomes in women with SLE from the RELESSER cohort after 12 years of follow-up. METHODS: A multicentre retrospective observational study was conducted. In addition to data from the RELESSER register, data were collected on obstetric/gynaecological variables and treatments received. The number of term pregnancies was compared between women with pregnancies before and after the diagnosis of SLE. Further, clinical and laboratory characteristics were compared between women with pregnancies before and after the diagnosis, on the one hand, and with and without complications during pregnancy, on the other. Bivariate and multivariate analyses were carried out to identify factors potentially associated with complications during pregnancy. RESULTS: A total of 809 women were included, with 1869 pregnancies, of which 1395 reached term. Women with pregnancies before the diagnosis of SLE had more pregnancies (2.37 vs 1.87) and a higher rate of term pregnancies (76.8% vs 69.8%, p < 0.001) compared to those with pregnancies after the diagnosis. Women with pregnancies before the diagnosis were diagnosed at an older age (43.4 vs 34.1 years) and had more comorbidities. No differences were observed between the groups with pregnancies before and after diagnosis in antibody profile, including anti-dsDNA, anti-Sm, anti-Ro, anti-La, lupus anticoagulant, anticardiolipin or anti-beta-2-glycoprotein. Overall, 114 out of the 809 women included in the study experienced complications during pregnancy, including miscarriage, preeclampsia/eclampsia, foetal death, and/or preterm birth. Women with complications had higher rates of antiphospholipid syndrome (40.5% vs 9.9%, p < 0.001) and higher rates of positivity for IgG anticardiolipin (33.9% vs 21.3%, p = 0.005), IgG anti-beta 2 glycoprotein (26.1% vs 14%, p = 0.007), and IgM anti-beta 2 glycoprotein (26.1% vs 16%, p = 0.032) antibodies, although no differences were found regarding lupus anticoagulant. Among the treatments received, only heparin was more commonly used by women with pregnancy complications. We did not find differences in corticosteroid or hydroxychloroquine use. CONCLUSIONS: The likelihood of term pregnancy is higher before the diagnosis of SLE. In our cohort, positivity for anticardiolipin IgG and anti-beta-2- glycoprotein IgG/IgM, but not lupus anticoagulant, was associated with a higher risk of poorer pregnancy outcomes.


Subject(s)
Antiphospholipid Syndrome , Lupus Erythematosus, Systemic , Pregnancy Complications , Premature Birth , Rheumatology , Pregnancy , Humans , Infant, Newborn , Female , Pregnancy Outcome/epidemiology , Premature Birth/epidemiology , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/drug therapy , Antiphospholipid Syndrome/diagnosis , Antiphospholipid Syndrome/epidemiology , Antiphospholipid Syndrome/complications , Pregnancy Complications/epidemiology , Retrospective Studies , beta 2-Glycoprotein I , Anticoagulants , Immunoglobulin G , Immunoglobulin M
2.
Semin Arthritis Rheum ; 52: 151946, 2022 02.
Article in English | MEDLINE | ID: mdl-35033377

ABSTRACT

BACKGROUND/OBJECTIVES: Factors associated with chronic heart failure (CHF) in patients with systemic lupus erythematosus (SLE) have received little attention. Recent data on the use of hydroxychloroquine in the treatment of SARS-CoV-2 infection have cast doubt on its cardiac safety. The factors associated with CHF, including therapy with antimalarials, were analyzed in a large multicenter SLE cohort. METHODS: Cross-sectional study including all patients with SLE (ACR-1997 criteria) included in the Spanish Society of Rheumatology Lupus Register (RELESSER), based on historically gathered data. Patients with CHF prior to diagnosis of SLE were excluded. A multivariable analysis exploring factors associated with CHF was conducted. RESULTS: The study population comprised 117 patients with SLE (ACR-97 criteria) and CHF and 3,506 SLE controls. Ninety percent were women. Patients with CHF were older and presented greater SLE severity, organ damage, and mortality than those without CHF. The multivariable model revealed the factors associated with CHF to be ischemic heart disease (7.96 [4.01-15.48], p < 0.0001), cardiac arrhythmia (7.38 [4.00-13.42], p < 0.0001), pulmonary hypertension (3.71 [1.84-7.25], p < 0.0002), valvulopathy (6.33 [3.41-11.62], p < 0.0001), non-cardiovascular damage (1.29 [1.16-1.44], p < 0.000) and calcium/vitamin D treatment (5.29 [2.07-16.86], p = 0.0015). Female sex (0.46 [0.25-0.88], p = 0.0147) and antimalarials (0.28 [0.17-0.45], p < 0.000) proved to be protective factors. CONCLUSIONS: Patients with SLE and CHF experience more severe SLE. Treatment with antimalarials appears to confer a cardioprotective effect.


Subject(s)
Antimalarials , COVID-19 , Heart Failure , Lupus Erythematosus, Systemic , Rheumatology , Antimalarials/therapeutic use , Cross-Sectional Studies , Female , Heart Failure/drug therapy , Heart Failure/epidemiology , Humans , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/drug therapy , Registries , SARS-CoV-2
3.
Psychol Med ; : 1-12, 2021 Apr 16.
Article in English | MEDLINE | ID: mdl-33858527

ABSTRACT

BACKGROUND: Bipolar disorder (BD) represents one of the most therapeutically complex psychiatric disorders. The development of a feasible comprehensive psychological approach to complement pharmacotherapy to improve its clinical management is required. The main objective of the present randomized controlled trial (RCT) was to test the efficacy of a novel adjunctive treatment entitled integrative approach in patients with BD, including: psychoeducation, mindfulness training, and functional remediation. METHODS: This is a parallel two-armed, rater-blind RCT of an integrative approach plus treatment as usual (TAU), v. TAU alone. Participants were recruited at the Hospital Clinic of Barcelona and randomized to one of the two conditions. They were assessed at baseline and after finishing the intervention. The main outcome variable included changes in psychosocial functioning assessed through the Functioning Assessment Short Test (FAST). RESULTS: After finishing the treatment, the repeated-measures analyses revealed a significant group × time interaction in favor of the patients who received the integrative approach (n = 28) compared to the TAU group (n = 37) (Pillai's trace = 0.10; F(1,57) = 6.9; p = 0.01), improving the functional outcome. Significant effects were also found in two out of the six domains of the FAST, including the cognitive domain (Pillai's trace = 0.25; F(1,57) = 19.1; p < 0.001) and leisure time (Pillai's trace = 0.11; F(1,57) = 7.15; p = 0.01). Regarding the secondary outcomes, a significant group × time interaction in Hamilton Depression Rating Scale changes was detected (Pillai's trace = 0.08; F(1,62) = 5.6; p = 0.02). CONCLUSION: This preliminary study suggests that the integrative approach represents a promising cost-effective therapy to improve psychosocial functioning and residual depressive symptoms in patients suffering from BD.

4.
Psychiatry Res ; 297: 113709, 2021 03.
Article in English | MEDLINE | ID: mdl-33429248

ABSTRACT

The ability of attributing mental states to oneself and to the others (theory of mind, ToM) is impaired in schizophrenia. ToM is not a monolithic function, it includes different capacities: some implies the decoding of affective states, others the reasoning about mental states. We have developed the BAT, a Battery to Assess Theory of mind abilities in adult psychotic subjects in an ecological audiovisual format. The performance on the BAT and three other test of social cognition was compared in a sample of schizophrenic patients with a control group. The samples were matched in terms of age and premorbid IQ. The BAT was sensitive to detect the ToM impairments in schizophrenia, showed good internal consistency and concurrent validity. The area under the ROC curves established a cutoff point that would correctly classify controls and patients in a 96.6% of cases. The factorial analysis isolated two factors: empathy and reasoning, with a good adjustment. Our results showed that the BAT could be a valid, ecological and usable tool to assess ToM in psychotic patients, with good psychometric properties, that would allow obtaining a more complete profile of their impairment.


Subject(s)
Schizophrenia/diagnosis , Schizophrenic Psychology , Social Perception , Theory of Mind/physiology , Adult , Emotions , Female , Humans , Male , Middle Aged , Psychometrics
5.
Rev. psiquiatr. salud ment. (Barc., Ed. impr.) ; 13(3): 165-173, jul.-sept. 2020. tab
Article in English | IBECS | ID: ibc-199847

ABSTRACT

INTRODUCTION: Bipolar disorder is related to a high level of personal, familial, social and economic burden. There is a need for feasible adjunctive psychological interventions easy to implement in clinical practice in order to enhance aspects that medication alone cannot achieve. This study aims to evaluate the impact of a 12-session adjunctive integrative program designed for patients with bipolar disorder. METHODS: This is a single-blind prospective, randomized controlled trial involving a total of 132 outpatients with bipolar disorder who will be recruited from the Hospital Clinic of Barcelona. All participants will be randomly assigned to two arms. All the patients will receive treatment as usual (TAU) but in addition the experimental group will receive an integrative approach consisting of 12-sessions of 90 min each in which contents of psychoeducation for patients have been combined with a session for family members, and complemented with aspects related to health promotion, mindfulness training, and strategies for cognitive and functional enhancement. The whole sample will be assessed at baseline, after completion (3-months) and at 12 months from baseline regarding demographic and clinical variables, psychosocial and cognitive functioning, wellbeing and quality of life. The primary outcome measure will be improvement in psychosocial functioning. CONCLUSIONS: If the integrative approach is effective, it would allow clinicians to cover different areas that may be affected by bipolar disorder, by means of a brief intervention that can therefore be easily generalized to clinical practice


INTRODUCCIÓN: El trastorno bipolar se asocia a un nivel elevado de carga personal, familiar, social y económica. Existe la necesidad de intervenciones psicológicas complementarias factibles y fáciles de implementar en la práctica clínica para mejorar aspectos que la medicación no consigue alcanzar. Este estudio tiene como objetivo evaluar el impacto de un programa integral de 12 sesiones complementario al tratamiento farmacológico para pacientes con trastorno bipolar. MÉTODOS: Ensayo clínico aleatorizado, controlado, a simple ciego. Serán reclutados del Hospital Clínic de Barcelona 132 pacientes ambulatorios diagnosticados de trastorno bipolar. Los participantes serán asignados aleatoriamente a dos grupos. Todos los pacientes recibirán el tratamiento habitual (TAU) pero, además, el grupo experimental recibirá un abordaje integral que consistirá en 12 sesiones de 90 min en las que se han combinado los contenidos de psicoeducación para pacientes con una sesión para familiares, complementándose con aspectos relacionados con la promoción de la salud, el entrenamiento en atención plena y estrategias para la potenciación cognitiva y funcional. La muestra completa será evaluada al inicio del estudio, a los 3 meses y a los 12 meses de seguimiento respecto a variables sociodemográficas y clínicas, de funcionamiento psicosocial y cognitivo, bienestar y calidad de vida. El principal resultado esperado será la mejoría en el funcionamiento psicosocial. CONCLUSIONES: Si el abordaje integral es efectivo, permitiría a los clínicos cubrir diferentes áreas que pueden verse afectadas por el trastorno bipolar, mediante una breve intervención que, por lo tanto, puede generalizarse fácilmente a la práctica clínica


Subject(s)
Humans , Bipolar Disorder/therapy , Mindfulness/methods , Cognitive Behavioral Therapy/methods , Cognitive Remediation/methods , Comprehensive Health Care/methods , Combined Modality Therapy/methods , Prospective Studies , Patient Education as Topic/methods , Evaluation of Results of Therapeutic Interventions
6.
Rev Psiquiatr Salud Ment (Engl Ed) ; 13(3): 165-173, 2020.
Article in English, Spanish | MEDLINE | ID: mdl-32651030

ABSTRACT

INTRODUCTION: Bipolar disorder is related to a high level of personal, familial, social and economic burden. There is a need for feasible adjunctive psychological interventions easy to implement in clinical practice in order to enhance aspects that medication alone cannot achieve. This study aims to evaluate the impact of a 12-session adjunctive integrative program designed for patients with bipolar disorder. METHODS: This is a single-blind prospective, randomized controlled trial involving a total of 132 outpatients with bipolar disorder who will be recruited from the Hospital Clinic of Barcelona. All participants will be randomly assigned to two arms. All the patients will receive treatment as usual (TAU) but in addition the experimental group will receive an integrative approach consisting of 12-sessions of 90min each in which contents of psychoeducation for patients have been combined with a session for family members, and complemented with aspects related to health promotion, mindfulness training, and strategies for cognitive and functional enhancement. The whole sample will be assessed at baseline, after completion (3-months) and at 12 months from baseline regarding demographic and clinical variables, psychosocial and cognitive functioning, wellbeing and quality of life. The primary outcome measure will be improvement in psychosocial functioning. CONCLUSIONS: If the integrative approach is effective, it would allow clinicians to cover different areas that may be affected by bipolar disorder, by means of a brief intervention that can therefore be easily generalized to clinical practice. TRIAL REGISTRATION: NCT04031560. Date registered July 24, 2019.

7.
J Affect Disord ; 274: 1113-1121, 2020 09 01.
Article in English | MEDLINE | ID: mdl-32663939

ABSTRACT

BACKGROUND: The efficacy of adjunctive group psychoeducation in bipolar disorder has been proven although treatment response differ among individuals. The aim of this study was to characterize responders and non-responders to group psychoeducation in order to identify baseline variables that could predict treatment response. METHODS: The sample was composed of 103 medicated euthymic patients with bipolar disorder referred to 21 sessions of group psychoeducation (6 months). Sociodemographic and clinical variables, temperament, circadian rhythms, BDNF, cognitive and psychosocial functioning were collected. At the 18-month endpoint, the patients were split in two groups on the basis of having suffered any recurrence. Significant group differences were included in a logistic regression analysis. RESULTS: Ninety patients out of 103 engaged in group psychoeducation, 47 of whom (52.2%) responded to psychoeducation and 43 (47.8%) did not. Recurrences occurred more often in the follow-up, the most common being depression. Responders and non-responders differed in gender, age at diagnosis, latency of diagnosis, temperament, attention composite score and BDNF. Lower age at diagnosis of bipolar disorder, lower cyclothimic temperament scores and being male -which was associated with bipolar type I and a trend to more previous manic episodes- were significantly related to a better response to psychoeducation in the regression analysis. LIMITATIONS: No control group. CONCLUSIONS: This study identifies age at diagnosis as a significant modifiable risk factor of treatment response, highlighting the need for early identification of bipolar disorder. Existing programs should be adjusted to the characteristics of specific subpopulations in the framework of a personalized approach.


Subject(s)
Bipolar Disorder , Bipolar Disorder/therapy , Humans , Longitudinal Studies , Male , Prospective Studies , Recurrence , Treatment Outcome
8.
J Rheumatol ; 47(2): 234-240, 2020 02.
Article in English | MEDLINE | ID: mdl-30988123

ABSTRACT

OBJECTIVE: To describe the incidence of bacteremia in a large multicentric cohort of patients with systemic lupus erythematosus (SLE) and their clinical characteristics and to identify risk factors. METHODS: All bacteremic episodes from the Spanish RELESSER registry were included. Clinical and laboratory characteristics concerning bacteremia and SLE status, as well as comorbidities at the time of infection, were retrospectively collected. A comparison with sex- and age-matched SLE controls without bacteremia was made. A logistic regression was conducted. RESULTS: The study included 114 episodes of bacteremia in 83 patients. The incidence rate was 2.7/1000 patient-years. At the time of bacteremia, the median age was 40.5 (range: 8-90) years, and 88.6% of patients were female. The Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index was 4 [interquartile range (IQR) 8]; 41% had an SLE flare (66% severe); Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index was 3 (IQR 4). A comorbidity was recorded in 64% of cases. At the time of bacteremia, 88.6% received corticosteroids (68.6% > 10 mg/day) and 57% immunosuppressors. Gram-negative bacilli, most frequently Escherichia coli (29.8%), caused 52.6% of the episodes. The bacteremia-related mortality was 14% and bacteremia was recurrent in 27.2% of cases. A dose-response relationship was found between corticosteroids and bacteremia risk. In the multivariate analysis, these factors were associated with bacteremia: elevated creatinine (OR 1.31, 95% CI 1.01-1.70; p = 0.045), diabetes (OR 6.01, 95% CI 2.26-15.95; p < 0.001), cancer (OR 5.32, 95% CI 2.23-12.70; p < 0.001), immunosuppressors (OR 6.35, 95% CI 3.42-11.77; p < 0.001), and damage (OR 1.65, 95% CI 1.31-2.09; p < 0.001). CONCLUSION: Bacteremia occurred mostly in patients with active SLE and was frequently associated with severe flares and corticosteroid use. Recurrence and mortality were high. Immunosuppressors, comorbidities, and disease-related damage were associated with bacteremia.


Subject(s)
Bacteremia/complications , Bacteremia/epidemiology , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/epidemiology , Registries , Adolescent , Adrenal Cortex Hormones/adverse effects , Adult , Aged , Aged, 80 and over , Bacteremia/chemically induced , Child , Comorbidity , Dose-Response Relationship, Drug , Female , Humans , Immunosuppressive Agents/adverse effects , Incidence , Logistic Models , Lupus Erythematosus, Systemic/drug therapy , Male , Middle Aged , Retrospective Studies , Risk Factors , Severity of Illness Index , Spain/epidemiology , Treatment Outcome , Young Adult
9.
Eur Neuropsychopharmacol ; 29(6): 701-710, 2019 06.
Article in English | MEDLINE | ID: mdl-31076186

ABSTRACT

The main aim of this study is to evaluate the impact of functional remediation (FR) in serum brain derived neurotrophic factor (BDNF) levels in euthymic adult patients with Bipolar Disorder (BD). A total of 128 participants were recruited at the Hospital Clinic of Barcelona. They were assessed at baseline and at the end of follow-up by the means of Hamilton Depression Scale (HAM-D), Young Mania Rating Scale (YMRS) and Functioning Assessment Short Test (FAST), as well as a clinical structured interview to collect clinical and demographic variables of interest. Blood samples were also collected to assess BDNF levels. After baseline assessment, patients received FR, Psychoeducation or treatment as usual (TAU). One hundred and two out of 126 participants finished the study distributed as follows: FR group (n = 39); Psychoeducation group (n = 47) and TAU group (n = 16). Longitudinal repeated-measures analyses addressing the treatment effect on BDNF levels showed non-significant differences between the three groups (Pillai's trace = 0.06; F(2,97)= 0.28; p = 0.75), suggesting no interaction between treatment allocation and time on BDNF levels. The results of this study suggest that FR has no effect on peripheral BDNF levels in euthymic patients with BD, despite the improvement in psychosocial functioning.


Subject(s)
Bipolar Disorder/metabolism , Bipolar Disorder/therapy , Brain-Derived Neurotrophic Factor/blood , Adolescent , Adult , Affect , Aged , Bipolar Disorder/psychology , Cognitive Behavioral Therapy , Diagnostic and Statistical Manual of Mental Disorders , Female , Follow-Up Studies , Humans , Longitudinal Studies , Male , Middle Aged , Neuropsychological Tests , Patient Education as Topic , Psychiatric Status Rating Scales , Treatment Outcome , Young Adult
10.
Int J Neuropsychopharmacol ; 20(8): 670-680, 2017 08 01.
Article in English | MEDLINE | ID: mdl-28498954

ABSTRACT

Over the last decade, there has been a growing appreciation of the importance of identifying and treating cognitive impairment associated with bipolar disorder, since it persists in remission periods. Evidence indicates that neurocognitive dysfunction may significantly influence patients' psychosocial outcomes. An ever-increasing body of research seeks to achieve a better understanding of potential moderators contributing to cognitive impairment in bipolar disorder in order to develop prevention strategies and effective treatments. This review provides an overview of the available data from studies examining treatments for cognitive dysfunction in bipolar disorder as well as potential novel treatments, from both pharmacological and psychological perspectives. All these data encourage the development of further studies to find effective strategies to prevent and treat cognitive impairment associated with bipolar disorder. These efforts may ultimately lead to an improvement of psychosocial functioning in these patients.


Subject(s)
Bipolar Disorder/complications , Bipolar Disorder/therapy , Cognitive Dysfunction/prevention & control , Cognitive Dysfunction/therapy , Bipolar Disorder/psychology , Cognitive Dysfunction/etiology , Humans
11.
Rheumatol Int ; 37(4): 647-656, 2017 Apr.
Article in English | MEDLINE | ID: mdl-27815703

ABSTRACT

To develop a disease activity index for patients with uveitis (UVEDAI) encompassing the relevant domains of disease activity considered important among experts in this field. The steps for designing UVEDAI were: (a) Defining the construct and establishing the domains through a formal judgment of experts, (b) A two-round Delphi study with a panel of 15 experts to determine the relevant items, (c) Selection of items: A logistic regression model was developed that set ocular inflammatory activity as the dependent variable. The construct "uveitis inflammatory activity" was defined as any intraocular inflammation that included external structures (cornea) in addition to uvea. Seven domains and 15 items were identified: best-corrected visual acuity, inflammation of the anterior chamber (anterior chamber cells, hypopyon, the presence of fibrin, active posterior keratic precipitates and iris nodules), intraocular pressure, inflammation of the vitreous cavity (vitreous haze, snowballs and snowbanks), central macular edema, inflammation of the posterior pole (the presence and number of choroidal/retinal lesions, vascular inflammation and papillitis), and global assessment from both (patient and physician). From all the variables studied in the multivariate model, anterior chamber cell grade, vitreous haze, central macular edema, inflammatory vessel sheathing, papillitis, choroidal/retinal lesions and patient evaluation were included in UVEDAI. UVEDAI is an index designed to assess the global ocular inflammatory activity in patients with uveitis. It might prove worthwhile to motorize the activity of this extraarticular manifestation of some rheumatic diseases.


Subject(s)
Inflammation/diagnosis , Uveitis/diagnosis , Adult , Aged , Female , Humans , Male , Middle Aged , Severity of Illness Index
12.
Schizophr Bull ; 41(6): 1387-96, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26006264

ABSTRACT

The effectiveness of cognitive remediation therapy (CRT) for the neuropsychological deficits seen in schizophrenia is supported by meta-analysis. However, a recent methodologically rigorous trial had negative findings. In this study, 130 chronic schizophrenic patients were randomly assigned to computerized CRT, an active computerized control condition (CC) or treatment as usual (TAU). Primary outcome measures were 2 ecologically valid batteries of executive function and memory, rated under blind conditions; other executive and memory tests and a measure of overall cognitive function were also employed. Carer ratings of executive and memory failures in daily life were obtained before and after treatment. Computerized CRT was found to produce improvement on the training tasks, but this did not transfer to gains on the primary outcome measures and most other neuropsychological tests in comparison to either CC or TAU conditions. Nor did the intervention result in benefits on carer ratings of daily life cognitive failures. According to this study, computerized CRT is not effective in schizophrenia. The use of both active and passive CCs suggests that nature of the control group is not an important factor influencing results.


Subject(s)
Cognition Disorders/rehabilitation , Cognitive Behavioral Therapy/methods , Executive Function/physiology , Memory Disorders/rehabilitation , Schizophrenia/rehabilitation , Therapy, Computer-Assisted/methods , Adult , Aged , Cognition Disorders/etiology , Female , Humans , Male , Memory Disorders/etiology , Middle Aged , Schizophrenia/complications , Treatment Failure , Young Adult
13.
Med. clín (Ed. impr.) ; 138(5): 199-201, mar. 2012.
Article in Spanish | IBECS | ID: ibc-98076

ABSTRACT

Fundamento y objetivo: El objetivo del trabajo es evaluar la efectividad de las dosis habituales de suplementos de vitamina D (25[OH]D) para alcanzar valores séricos óptimos (30ng/ml). Pacientes y método: Estudio transversal en 165 mujeres con osteoporosis posmenopáusica, tratadas con suplementos de vitamina D oral con dosis superiores a 800UI/día durante al menos 3 meses. Se dividió a las pacientes en 3 grupos: grupo 1, 800-1.000UI/día; grupo 2, 1.001-1.600UI/día; grupo 3, >1.600UI/día. Se comparó la proporción de pacientes con valores séricos superiores a 20, 30 y 40ng/ml. Resultados: La edad media (DE) fue de 69 (10) años. El porcentaje de pacientes con valores superiores a 20ng/ml fue del 79,5% (intervalo de confianza del 95% [IC 95%] 63,5-88,5), 92,7% (IC 95% 78,7-96) y 97,6% (IC 95% 90,6-100) en los grupos 1, 2 y 3, respectivamente (p=0,009), el de pacientes con valores superiores a 30ng/ml del 27,7% (IC 95% 14,7-44,7), 53,6% (IC 95% 37,6-70) y 90,2% (IC 95% 81,2-96,6), respectivamente (p<0,001) y el de pacientes con valores superiores a 40ng/ml del 7,2% (IC 95% 1-20), 24,4% (IC 95% 12-40) y 61% (IC 95% 49-72), respectivamente (p<0,001). Conclusiones: Las dosis diarias recomendadas de suplementos de vitamina D (800-1.000UI) pueden ser insuficientes para conseguir valores séricos óptimos en mujeres osteoporóticas posmenopáusicas (AU)


Background and objective: To assess the effectiveness of currently recommended daily intakes of vitamin D (25[OH]D) to bring optimal serum concentrations (30ng/ml) in postmenopausal osteoporotic women. Patients and methods: We reviewed 25(OH)D serum concentrations in 165 consecutive osteoporotic postmenopausal women who were taking oral vitamin D daily supplements above 800IU during at least 3 months. The proportion of patients who achieved 25(OH)D levels of 20, 30 and 40ng/ml were compared according to daily vitamin D intakes (group 1: 800-1,000IU, group 2: 1,001-1,600IU, group 3:>1,600IU). Results: Mean patient age was 69 (10) years. Percentage of patients with serum 25(OH)D levels above 20ng/ml was 79.5% (63.5-88.5%), 92.7%(78.7-96%) and 97.6% (90.6-100%) in group 1, 2, and 3 patients, respectively (P=.009). Serum levels above 30ng/ml were achieved in 27.7% (14.7-44.7%), 53.6% (37.6-70%) and 90.2% (81.2-96.6%), respectively (P<.001). Serum levels above 40ng/ml were reached in 7.2% (1-20%), 24.4% (12-40%) and 61% (49-72%), respectively (P<.001). Conclusion: Daily reference intakes of vitamin D supplements (800-1,000IU) may be insufficient to achieve optimal serum levels of vitamin D in postmenopausal osteoporotic women (AU)


Subject(s)
Humans , Female , Aged , Osteoporosis, Postmenopausal/blood , Vitamin D/blood , Cholecalciferol/deficiency , Vitamin D/administration & dosage , Cholecalciferol/administration & dosage , Dietary Supplements , Cross-Sectional Studies
14.
Med Clin (Barc) ; 138(5): 199-201, 2012 Mar 03.
Article in Spanish | MEDLINE | ID: mdl-22197363

ABSTRACT

BACKGROUND AND OBJECTIVE: To assess the effectiveness of currently recommended daily intakes of vitamin D (25[OH]D) to bring optimal serum concentrations (30ng/ml) in postmenopausal osteoporotic women. PATIENTS AND METHODS: We reviewed 25(OH)D serum concentrations in 165 consecutive osteoporotic postmenopausal women who were taking oral vitamin D daily supplements above 800IU during at least 3 months. The proportion of patients who achieved 25(OH)D levels of 20, 30 and 40ng/ml were compared according to daily vitamin D intakes (group 1: 800-1,000IU, group 2: 1,001-1,600IU, group 3:>1,600IU). RESULTS: Mean patient age was 69 (10) years. Percentage of patients with serum 25(OH)D levels above 20ng/ml was 79.5% (63.5-88.5%), 92.7%(78.7-96%) and 97.6% (90.6-100%) in group 1, 2, and 3 patients, respectively (P=.009). Serum levels above 30ng/ml were achieved in 27.7% (14.7-44.7%), 53.6% (37.6-70%) and 90.2% (81.2-96.6%), respectively (P<.001). Serum levels above 40ng/ml were reached in 7.2% (1-20%), 24.4% (12-40%) and 61% (49-72%), respectively (P<.001). CONCLUSION: Daily reference intakes of vitamin D supplements (800-1,000IU) may be insufficient to achieve optimal serum levels of vitamin D in postmenopausal osteoporotic women.


Subject(s)
Dietary Supplements , Osteoporosis, Postmenopausal/drug therapy , Vitamin D Deficiency/drug therapy , Vitamin D/analogs & derivatives , Vitamin D/therapeutic use , Administration, Oral , Aged , Dose-Response Relationship, Drug , Drug Monitoring , Female , Humans , Middle Aged , Nutrition Policy , Osteoporosis, Postmenopausal/blood , Prospective Studies , Reference Standards , Treatment Failure , Vitamin D/administration & dosage , Vitamin D/blood , Vitamin D Deficiency/blood , Vitamin D Deficiency/complications
SELECTION OF CITATIONS
SEARCH DETAIL
...